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Abstract: 
Literature shows that Flaviviruses cause a variety of diseases, including fevers, encephalitis, and hemorrhagic fevers. NS3 is a multifunctional protein with an N-
terminal protease domain (NS3pro) that is responsible for proteolytic processing of the viral polyprotein, and a C-terminal region that contains an RNA 
triphosphatase, RNA helicase and RNA-stimulated NTPase domain that are essential for RNA replication. Therefore, NS3 protein is the preferential choice for 
inhibition to stop the proteolytic processing. Hence, the 3D structure of NS3 protein was modeled using homology modeling by MODELLER 9v7. Evaluation of 
the constructed NS3 protein models were done by PROCHECK, VERYFY3D and through ProSA calculations. Ligands for the catalytic triad were designed using 
LIGBUILDER. The NS3 protein’s catalytic triad was explored to find out the critical interactions pattern for inhibitor binding using molecular docking 
methodology using AUTODOCK Vina. It should be noted that these predicted data should be validated using suitable assays for further consideration. 
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Background: 
Flaviviruses are a group of more than 70 enveloped RNA viruses that cause 
serious diseases in humans and animals. Most of them are arthropod-borne 
viruses (arboviruses) and are transmitted to vertebrate hosts by either 
mosquitoes or ticks [1]. Flaviviruses cause a variety of diseases, including 
fevers, encephalitis, and hemorrhagic fevers [2]. It is believed that JE is 
responsible for more than 50,000 cases of encephalitis annually, with at least 
10,000 deaths. Some 2.5 billion people – two fifths of the world's population – 
are now at risk for dengue, and despite 50 years of efforts, there is no dengue 
vaccine available on the market. WHO currently estimates that there may be 50 
million dengue infections worldwide every year. In 2007 alone, there were 
more than 890,000 reported cases of dengue in the Americans, of which 26,000 
cases were diagnosed as Dengue Hemorrhagic Fever (DHF). There are almost 
100 asymptomatic infections for every reported flavivirus case, and the case 
fatality rates vary from 1 to 30% depending on the infecting flavivirus [WHO]. 
The family Flaviviridae consists of approximately 70 viruses, nearly 40 of 
which cause human disease [3]. Dengue virus (DENV), Japanese encephalitis 
virus (JEV), Murray Valley encephalitis virus (MVEV), Usutu virus (USUV), 
and West Nile virus (WNV) are a member of the genus Flavivirus and family 
Flaviviridae [4, 5].  
 
Flaviviruses have a positive-sense single-stranded RNA (ssRNA) genome 
(approximately 11 kb) that encodes one large open reading frame containing a 
5’ type 1 cap and conserved RNA structures at both the 5’ and 3’ untranslated 
regions that are important for viral genome translation and replication. The  
 
genomic RNA is translated into a single polyprotein precursor consisting of 
three structural (C [capsid], prM [membrane], and E [envelope]) and seven 
nonstructural (NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5) proteins 
arranged in the order C-prM-E-NS1-NS2a-NS2b-NS3-NS4a-NS4b-NS5 [6]. 
Only the structural proteins become part of the mature, infectious virion, 
whereas the nonstructural proteins are involved in polyprotein processing, viral 
RNA synthesis, and virus morphogenesis [7]. NS3 is a multifunctional protein 
with an N-terminal protease domain (NS3pro) that is responsible for proteolytic 
processing of the viral polyprotein, and a C-terminal region that contains an 
RNA triphosphatase, RNA helicase and RNA-stimulated NTPase domain that 
are essential for RNA replication. The serine protease domain of NS3 plays a 
central role in the replicative cycle of Flaviviruses [8] and is therefore a 
possible target for anti-flaviviral compounds [9]. 
 
In this in-silico study, we designed an inhibitor which showed inhibitory 
activity towards flavivirus (DENV, JEV, MVEV, USUV, and WNV) NS3 
protein. The binding interactions between this inhibitor and NS3 protein were 
studied by docking methods using AutoDock vina software. The aim of this 
study was to get a better ligand that could inhibit polyprotein processing of 
Flavivirus (DENV, JEV, MVEV, USUV, and WNV), and to better understand 
the interactions between the inhibitor and the enzyme’s binding sites via 
computational docking methods. We hope, this Drug will get success to clear 
out all the phases of clinical trial and it will be effective drug in the cure of 
encephalitis and hemorrhagic fevers. BIOINFORMATION  open access 
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Figure 1: The sequence alignment between the five NS3 proteins of MVEV, DENV, JEV, USUV and WNV. All three major amino acids forming the Catalytic 
Triad (H51, D75, and S135) have been highlighted. 
 
Methodology: 
Sequence alignment:  
The protein sequences of NS3 were obtained from GenBank 
(http://www.ncbi.nlm.nih.gov/genbank/) database (MVEV (NP_722535.1), 
JEV (NP_775670.1), USUV (YP_164814.1) and WNV (NP_776018.1)) and 
Swiss Prot (DENV (P27909)). Using the BLAST P 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) through NCBI, the homologous 
structure of MVEV NS3 was identified, which was used as template for the 
homology modeling. The sequence alignment was done using the online 
version of ClustalW (http://www.ebi.ac.uk/Tools/msa/clustalw2/) (Figure 1). 
 
Homology modeling: 
BLASTP was used to identify the most suitable template for homology 
modeling of NS3 protein. The available structure of NS3 protein from MVEV 
in the Protein Database (PDB entry 2WV9) was used as a template for DENV, 
JEV, USUV and WNV. The homology modeling was carried out using the 
Modeller (http://www.salilab.org/modeller/) 9v7 program. The target and the 
template sequences were aligned using Modeller 9v7, a comparative protein 
modeling program, was used for homology modeling to generate the 3-D 
structures of NS3 protein for MVEV, DENV, JEV, USUV and WNV. The 
energy computations were done with the GROMOS 96 by implementation of 
Swiss-PdbViewer (http://www.expasy.org/spdbv). Figure 2 shows the 
superimposed NS3 3D models of JEV, MVV, WNV, USUV and DENV in 
cartoons view with Pymol software. 
 
 
Figure 2: Structural model Superposition of NS3 proteins for JEV (Green), 
MVV (Red), WNV (Blue), USUV (Yellow) and DENV (Cyan). 
Validation of the generated models: 
Different structure verification programs such as PROCHECK, VERIFY3D 
and ProSA (http://nihserver.mbi.ucla.edu/SAVES/) were used to evaluate the 
3D-model of NS3 protein. The above mentioned validation programs validate 
the predicted structure by checking various parameters. While PROCHECK, a 
structure verification program relies on Ramachandran plot [10], determines 
the quality of the predicted structure by assessing various parameters such as 
lengths, angles and planarity of the peptide bonds, geometry of the hydrogen 
bonds, and side chain conformations of protein structures as a function of 
atomic resolution. The Verify3D determines the compatibility of an atomic 
model (3D) with its own amino acid sequence (1D) by assigning a structural 
class based on its location and environment (alpha, beta, loop, polar, nonpolar 
etc.) and comparing the results to valid structures [11]. 
 
Inhibition site identification: 
The active sites were revealed on the basis of previous studies. The amino-
terminal domain contains the serine protease catalytic triad consisting of amino 
acid residues H51, D75, and S135 and the substrate-binding pocket is 
contained within NS3 protein [12, 13, 14].  
 
Generating novel ligands:  
The structure of the fragment, i.e. the “seed molecule” was revealed on the 
basis of previous studies of available inhibitors for NS3 protein [15]. The 
fragment “1 H-1, 2, 4-triazole” was identified on the basis of “Lipinski's Rule 
of Five” and may therefore represent suitable starting point for evolution of 
good quality lead compounds. The docking analysis of “1 H-1, 2, 4-triazole” 
compound with MVEV NS3 protein was carried out by HEX 
(http://hex.loria.fr/) docking software with default parameters. The 
conformation of the pre-placed “seed” ensuring the binding affinity decides the 
manner that ligands would be grown with Ligbuilder software. Novel ligands 
had been developed with Ligbuilder 
(http://mdl.ipc.pku.edu.cn/drug_design/work/ligbuilder.html) v1.2 software. 
We developed 100 novel ligands for the inhibitory site in NS3 protein.  
 
Virtual screening: 
Out of 100 novel ligands generated, 10 ligands were selected on the basis of 
maximum binding affinity measured in kcal/mol. The selected 10 ligands were 
then analyzed for drug- relevant properties based on “Lipinski’s rule of five” 
and other drug like properties of valid structures using OSIRIS Property 
Explorer (http://www.organic-chemistry.org/prog/peo/), Molsoft: Drug-
Likeness and molecular property explorer (http://www.molsoft.com/mprop/), 
and Molinspiration property explorer (http://www.molinspiration.com/cgi-
bin/properties). On the basis of binding affinity and drug like properties, one 
ligand (Figure 3F) was finally screened. 
 
Lead optimization: 
The goal of lead optimization is to improve the effectiveness of initial ‘hits’ 
from primary screening. There are many approaches to lead optimization, all of 
which have the same theme: reduce off-target effects, create an improved 
ADME/T profile and improve a compound’s efficacy. The lead optimization 
was performed using Toxtree (http://toxtree.sourceforge.net/) v1.60 software. 
 
Protein-ligand docking: 
The docking of ligands to the catalytic triad of NS3 protein for MVEV, DENV, 
JEV, USUV and WNV was performed using AutoDock Vina software. 
Docking was performed to obtain a population of possible conformations and 
orientations for the ligand at the binding site. Using the software, polar 
hydrogen atoms were added to the NS3 protein and its nonpolar hydrogen 
atoms were merged. All bonds of ligands were set to be rotatable. All 
calculations for protein-fixed ligand-flexible docking were done using the 
Lamarckian Genetic Algorithm (LGA) method. The grid box with a dimension 
of 20 x 20 x 20 points was used around the catalytic triad to cover the entire 
enzyme binding site and accommodate ligands to move freely. The best BIOINFORMATION  open access 
 
ISSN 0973-2063 (online) 0973-8894 (print)     
Bioinformation 6(2): 57-60 (2011)  59                                               © 2011 Biomedical Informatics 
 
conformation was chosen with the lowest docked energy, after the docking 
search was completed. The interactions of complex NS3 protein-ligand 
conformations, including hydrogen bonds and the bond lengths were analyzed 
using Swiss-PdbViewer v4.0 and Pymol software. 
 
 
Figure 3: The solvent-accessible surface of the protein is shown in color-coded 
atoms (white, carbon; red, oxygen; blue, nitrogen). Molecular docking of novel 
ligand onto NS3 protein of MVEV (A), JEV (B), USUV (C), WNV (D)  and 
DENV (E). Figure 3(F) represents the structure of novel ligand. 
 
Discussion: 
Sequence alignment of NS3 protein for MVEV, DENV, JEV, USUV and WNV 
f r o m  s a m e  f a m i l y  r e v e a l e d  M V E V  t o  b e  t h e  b e s t  t e m p l a t e  f o r  h o m o l o g y  
modeling as the MVEV shared 61% identity with DENV, 86% identity with 
JEV, 88% identity with USUV and 81% identity with WNV. The crystal 
structure of the NS3 protease-helicase from Murray Valley Encephalitis Virus 
(PDB entry 2WV9) was used as a template to predict the structure of NS3 
protein and the predicted 3D structure of NS3 protein was generated by 
Modeller and the structure with the lowest DOPE scores were selected. The 
qualities of the 3D models were evaluated using the PROCHECK program and 
assessed using the Ramachandran plot. It is evident from the Ramachandran 
plot that the predicted models have most favorable regions, the allowed 
regions, the generic regions and the disallowed regions. Such a percentage 
distribution of the protein residues determined by Ramachandran plot shows 
that the predicted models are of good quality. The models show all the main 
chain and side chain parameters to be in the ‘better’ region. The quality of the 
generated models of NS3 protein as evaluated by ProSA web server 
(https://prosa.services.came.sbg.ac.at/prosa.php) provided a z-score of -11.03 
(MVEV), -11.09 (JEV), -11.63 (USUV),-11.18 (WNV) and -7.06 (DENV) 
which falls within the range of values observed for the experimentally 
determined structures of similar lengths. The validity of the predicted model of 
NS3 protein was also verified by employing the structure verification server 
Verify-3D. The DOPE scores of NS3 protein were 63437.13672, 52417.43359, 
62345.25391, 63189.61719 and 62632.42969 for MVEV, DENV, JEV, USUV 
and WNV respectively. 
 
The Protein-ligand interaction plays a significant role in structure based drug 
designing. Overall, the best confirmation shows that the free energy of binding 
(ΔGbind kcal/mol) for the designed ligand were -5.9 kcal/mol, -6.0 kcal/mol, -
6.7 kcal/mol, -6.6 kcal/mol and -6.6 kcal/mol for MVEV, JEV, USUV, WNV 
and DENV respectively (Figure 3). The negative and low value of ΔGbind 
indicates strong favorable bonds between NS3 protein and the novel ligand 
indicating that the ligand was in its most favourable conformations. The 
information about the number of hydrogen bonds formed and catalytic site 
residues involved in protein-ligand complex are shown in Table 1 (see 
Supplementary material).  
 
Conclusion: 
In this study, we designed a novel ligand against NS3 protein of MVEV, 
DENV, JEV, USUV and WNV.  The molecular docking was applied to explore 
the binding mechanism and studies on the novel ligand against the NS3 protein 
showed that the free binding energy for the inhibitor was small, indicating that 
the ligand binds favorably to the binding site. The ligand was observed as the 
best inhibitor candidate, which may be considered as a potential ligand for 
treatment of diseases caused by flavivirus. The ligand thus developed is likely 
to inhibit viral infections, which share high sequence similarity with the five 
NS3 proteins of MVEV, DENV, JEV, USUV and WNV from same family. We 
plan to calculate ADME/T (Absorption, Distribution, Metabolism, Excretion / 
Toxicity) properties of the designed ligand using the available commercial 
ADME/T tools in future. 
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Supplementary material: 
 
Table 1: The number of Hydrogen bonds formed and the catalytic site residues involved in protein-ligand complex. 
Virus name  No. of Hydrogen bonds  Catalytic site residue(s) in Hydrogen bonding 
Murray Valley encephalitis virus  1  HIS 51 
Japanese encephalitis virus  3, 1  HIS 51, ASP 75 
Usutu virus  1  ASP 75 
West Nile virus  1  HIS 51 
Dengue  virus  1,1  HIS 51, ASP 75 
 